Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gland PharmaNSE:GLAND -1.05%84 EV-to-EBITDA is 19.97 as of Jul. 31, 2026, which is 2% below its 10-year median of 20.41. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,152.02 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 747 Drug Manufacturers companies, Gland Pharma ranks worse than 67.07% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gland Pharma's enterprise value is ₹383,711 Mil.
Gland Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹19,215 Mil. Therefore, Gland Pharma's EV-to-EBITDA for today is 19.97.
The historical rank and industry rank for Gland Pharma's EV-to-EBITDA or its related term are showing as below:
NSE:GLAND'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.47 Med: 20.41 Max: 47.22
Current: 19.97
During the past 9 years, the highest EV-to-EBITDA of Gland Pharma was 47.22. The lowest was 9.47. And the median was 20.41.
NSE:GLAND's EV-to-EBITDA is ranked worse than 67.07% of 747
companies
in the Drug Manufacturers industry
Industry Median: 12.88
vs NSE:GLAND: 19.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gland Pharma's PE Ratio (TTM) for today is calculated as:
Gland Pharma's share price for today is ₹2517.00.
Gland Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹62.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Gland Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gland Pharma's EV-to-EBITDA falls into.
Gland Pharma's current Enterprise Value is ₹383,711 Mil.
Gland Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹19,215 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (NSE:GLAND) has a EV-to-EBITDA of 19.97 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gland Pharma. This is near median its historical median of 20.41. Over the past decade, Gland Pharma's EV-to-EBITDA has ranged from 9.47 to 47.22. According to the industry distribution chart, Gland Pharma ranks #501 out of 747 companies in the Drug Manufacturers industry, placing it in the top 67.1%.
Is Gland Pharma's EV-to-EBITDA too high?
Gland Pharma's current EV-to-EBITDA of 19.97 is near median its 10-year median of 20.41. Over the past 10 years, this metric has ranged from a low of 9.47 to a high of 47.22. The Drug Manufacturers industry median EV-to-EBITDA is 12.88. Gland Pharma's value of 19.97 is 55% above this industry median. Based on the distribution chart, Gland Pharma ranks #501 out of 747 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #501 out of 747 companies for EV-to-EBITDA. This places Gland Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 12.88. Gland Pharma's value of 19.97 is 55% above this benchmark. Historically, Gland Pharma's own EV-to-EBITDA has ranged from 9.47 to 47.22 over the past decade. While the company's 10-year median is 20.41 vs. the industry median of 12.88, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.88, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current EV-to-EBITDA of 19.97 is 55% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gland Pharma. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current EV-to-EBITDA is 19.97, which is near median its own 10-year median of 20.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,152.02, compared to a current price of ₹2,517.00 — trading 17% above its estimated fair value. The current EV-to-EBITDA is 19.97, which is near median its 10-year median of 20.41 and 55% above the Drug Manufacturers industry median of 12.88. Gland Pharma's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current EV-to-EBITDA is 19.97 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,517.00 is trading 17% above its estimated GF Value™ of ₹2,152.02.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
EV-to-EBITDA: 19.97 (near median its 10-year median of 20.41)
GF Value™: ₹2,152.02 vs. price of ₹2,517.00 (17% above fair value)
Industry Position: 55% above the Drug Manufacturers median (#501 of 747)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score
Get the complete analysis for NSE:GLAND
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
